Silence Therapeutics (SLN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Are you having trouble logging in? Follow this step-by-step guide when logging in. You can download this information as a printer friendly version (603 KB) and also ...

No description, website, or topics provided.